Form 4: Enanta Pharmaceuticals Director Bruce Carter Acquires Stock Options

Director Bruce L.A. Carter of Enanta Pharmaceuticals acquired stock options exercisable for 15,700 shares of common stock on March 13, 2025.

Summary

• Bruce L.A. Carter, a director of Enanta Pharmaceuticals, acquired stock options on March 13, 2025.
• The options are for 15,700 shares of Enanta Pharmaceuticals common stock.
• The exercise price of the options is $6.83 per share.
• The options vest monthly over one year, starting March 13, 2025, with the final installment vesting before the 2026 annual meeting of stockholders.
• Carter also filed a Power of Attorney, effective July 24, 2024, granting certain individuals the authority to execute SEC filings on his behalf.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard disclosure of stock option grants, which is neither overtly positive nor negative.

Positives

• The acquisition of stock options by a director could be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The document does not contain specific forward-looking statements regarding the company's future performance, but the vesting schedule extends into the future.

Industry Context

This is a routine disclosure related to insider transactions, common in the pharmaceutical industry where stock options are frequently used as part of executive compensation packages.

Comparison to Industry Standards

• Stock option grants are a common component of compensation packages for directors and executives in the pharmaceutical industry.
• Companies like Gilead Sciences, Vertex Pharmaceuticals, and AbbVie also utilize stock options as part of their compensation strategy to align the interests of management with those of shareholders.

Stakeholder Impact

• The stock option grant aligns the director's interests with those of shareholders, potentially incentivizing actions that increase shareholder value.

Key Dates